- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06846671
BGB-16673에 대한 연구는 이전에 Bruton 티로신 키나제 (BTK) 및 B- 세포 백혈병/림프종 2 단백질 (BCL2) 억제제에 노출 된 만성 림프구 백혈병 참가자에서의 조사자가 선택한 것과 비교하여 연구 (CaDAnCe-302)
BTK 및 BCL2 주변에 이전에 노출 된 만성 림프구 백혈병 환자에서 조사자의 선택 (idelalisib + rituximab or rituximab 또는 venetoclax + venetoclax + rituximab reattment)과 비교하여 BGB-16673에 대한 3 상, 개방-라벨, 무작위 연구
The purpose of this study is to investigate the efficacy and safety of tacabrutideg compared with investigator's choice (idelalisib plus rituximab [for CLL only] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to both BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i).
연구 개요
상태
상세 설명
CLL (chronic lymphocytic leukemia) and SLL (small lymphocytic lymphoma) are slow-growing blood cancers that affect the same type of white blood cell (called B lymphocytes). They are considered different forms of the same disease. CLL mainly occurs in the blood and bone marrow, while SLL mainly affects the lymph nodes.
Tacabrutideg is a type of medicine called a BTK degrader. BTK (Bruton's tyrosine kinase) is a protein that helps cancer cells survive. Tacabrutideg is designed to attach to the BTK protein and tag it for removal, so that the body's own cellular "clean-up" system breaks it down and clears it away. When more BTK is removed from the body, it interferes with the signals needed for the cancer cells to multiply and survive and may also help overcome resistance caused by certain changes in BTK.
The purpose of this study is to test if tacabrutideg is safe and if it works in adults with CLL or SLL. The main goal of the study is to find the amount of time participants live without their disease getting worse after starting the study treatment.
This study has two treatment groups. Participants will be randomly assigned by chance, to one of the treatment groups. Participants and the study doctors will know what treatment is received during the study.
The study will enroll approximately 250 adults at multiple centers worldwide with CLL or SLL. The overall time to participate in this study is 36 months. Participants will make regular visits to the clinic for treatment, health checks, blood tests, and tumor and imaging tests.
Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 연락처
- 이름: Study Director
- 전화번호: 1.877.828.5568
- 이메일: clinicaltrials@beonemed.com
연구 장소
-
-
-
Amsterdam, 네덜란드, 1081 HV
- 모병
- Amsterdam Umc Vu Mc
-
-
-
-
Busan Gwang'yeogsi
-
Seogu, Busan Gwang'yeogsi, 대한민국, 49201
- 모병
- Dong A University Hospital
-
-
Daegu Gwang'yeogsi
-
Junggu, Daegu Gwang'yeogsi, 대한민국, 41944
- 모병
- Kyungpook National University Hospital
-
-
Gyeonggi-do
-
IlsandongGu GoyangSi, Gyeonggi-do, 대한민국, 10408
- 모병
- National Cancer Center (Korea)
-
-
Jeonnam-Gwangju S.M. City
-
HwasunGun, Jeonnam-Gwangju S.M. City, 대한민국, 58128
- 모병
- Chonnam National University Hwasun Hospital
-
-
Seoul Teugbyeolsi
-
GangnamGu, Seoul Teugbyeolsi, 대한민국, 06351
- 모병
- Samsung Medical Center
-
SeochoGu, Seoul Teugbyeolsi, 대한민국, 06591
- 모병
- The Catholic University of Korea, Seoul St Marys Hospital
-
Seoul, Seoul Teugbyeolsi, 대한민국, 03080
- 모병
- Seoul National University Hospital
-
-
-
-
-
Augsburg, 독일, 86156
- 모병
- Universitatsklinikum Augsburg
-
Berlin, 독일, 10715
- 모병
- Praxis Am Volkspark
-
Chemnitz, 독일, 09116
- 모병
- Klinikum Chemnitz Ggmbh
-
Essen, 독일, 45122
- 모병
- Universitatsklinikum Essen (Aor)
-
Frankfurt am Main, 독일, 60389
- 모병
- Centrum Fur Haematologie Und Onkologie Bethanien
-
Freiburg im Breisgau, 독일, 79106
- 모병
- Universitatsklinikum Freiburg I Br Klinik Fur Innere Medizin I
-
Hamburg, 독일, 20251
- 모병
- Universitatsklinikum Hamburg Eppendorf
-
Heidelberg, 독일, 69120
- 모병
- Universitatsklinikum Heidelberg
-
Homburg, 독일, 66421
- 모병
- Universitatsklinikum Des Saarlandes
-
Koblenz, 독일, 56068
- 모병
- Invo Institut Fur Versorgungsforschung in Der Onkologie
-
Leipzig, 독일, 04103
- 모병
- Universitaetsklinikum Leipzig Aor
-
Münster, 독일, 48149
- 모병
- Universitatsklinikum Munster Medizinische Klinik A
-
-
-
-
Arkansas
-
Jonesboro, Arkansas, 미국, 72401
- 모병
- St Bernards Medical Center
-
-
California
-
Los Angeles, California, 미국, 90095-3075
- 모병
- UCLA Department of Medicine Hematologyoncology
-
San Diego, California, 미국, 92103-2106
- 모병
- Scripps Prebys Cancer Center
-
Whittier, California, 미국, 90602
- 모병
- Pih Health Whittier Hospital
-
-
Colorado
-
Aurora, Colorado, 미국, 80012-5405
- 모병
- Rocky Mountain Cancer Centers (Williams) Usor
-
Golden, Colorado, 미국, 80401
- 모병
- Intermountain Health Lutheran Hospital Cancer Center of Colorado
-
-
Florida
-
Fort Myers, Florida, 미국, 33912
- 모병
- Florida Oncology and Hematology
-
Jacksonville, Florida, 미국, 32207-8432
- 모병
- Baptist Md Anderson Cancer Center
-
Weston, Florida, 미국, 33331-3609
- 모병
- Cleveland Clinic Florida
-
-
Georgia
-
Atlanta, Georgia, 미국, 30322-1013
- 모병
- Emory University Winship Cancer Institute
-
Atlanta, Georgia, 미국, 30342
- 모병
- Northside Cancer Center
-
-
Louisiana
-
Baton Rouge, Louisiana, 미국, 70808-4365
- 모병
- Our Lady of the Lake Hospital
-
-
Maryland
-
Bethesda, Maryland, 미국, 20817-7847
- 모병
- American Oncology Partners of Maryland Pa
-
-
Michigan
-
Grand Rapids, Michigan, 미국, 49503-2560
- 모병
- Corewell Health the Michigan Cancer Consortium
-
-
Minnesota
-
Minneapolis, Minnesota, 미국, 55455-0341
- 모병
- University of Minnesota
-
-
Missouri
-
Chesterfield, Missouri, 미국, 63017
- 모병
- St Lukes Center For Cancer Care
-
Springfield, Missouri, 미국, 65807-5288
- 모병
- Oncology Hematology Associates
-
-
Montana
-
Billings, Montana, 미국, 59102-6746
- 모병
- St Vincent Frontier Cancer Center
-
-
Nebraska
-
Omaha, Nebraska, 미국, 68130-2042
- 모병
- Oncology Hematology West, Pc Dba Nebraska Cancer Specialists
-
-
New York
-
New York, New York, 미국, 10065-6800
- 모병
- Memorial Sloan Kettering Cancer Center Mskcc
-
Shirley, New York, 미국, 11967
- 모병
- New York Cancer and Blood Specialists
-
Syracuse, New York, 미국, 13210-2306
- 모병
- Suny Upstate Medical University
-
Westbury, New York, 미국, 11590-5119
- 모병
- Optum Medical Care, Pc
-
-
Ohio
-
Cleveland, Ohio, 미국, 44106-1716
- 모병
- University Hospitals
-
Dayton, Ohio, 미국, 45415
- 모병
- Dayton Physician Network
-
-
Oregon
-
Eugene, Oregon, 미국, 97401
- 모병
- Oncology Associates of Oregon Willamette Valley Cancer Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, 미국, 15224
- 모병
- West Penn Hospital
-
York, Pennsylvania, 미국, 17403-5049
- 모병
- Cancer Care Associates of York
-
-
Texas
-
Temple, Texas, 미국, 76508-0001
- 모병
- Baylor Scott and White Health Medical Center Temple
-
Tyler, Texas, 미국, 75702-7522
- 모병
- Texas Oncology Tyler
-
-
-
-
-
Belo Horizonte, 브라질, 30110-022
- 모병
- CETUS
-
Brasília, 브라질, 70200-730
- 모병
- Hospital Sirio Libanes Brasilia
-
Curitiba, 브라질, 81520-060
- 모병
- Hospital Erasto Gaertner
-
Florianópolis, 브라질, 88020-210
- 모병
- Centro de Ensino E Pesquisa Em Oncologia de Santa Catarina (Cepen)
-
Joinville, 브라질, 89201-260
- 모병
- Instituto Joinvilense de Hematologia E Oncologia
-
Niterói, 브라질, 24020-096
- 모병
- Complexo Hospitalar de Niteroi
-
Novo Hamburgo, 브라질, 93510-223
- 모병
- Vida Hematologia
-
Porto Alegre, 브라질, 90110-270
- 모병
- Centro Gaucho Integrado de Oncologia Hospital Mae de Deus
-
Rio de Janeiro, 브라질, 22250-040
- 모병
- Oncoclinicas Rio de Janeiro Sa
-
Rio de Janeiro, 브라질, 22061-080
- 모병
- Hospital Sao Lucas Dasa Oncologia
-
Salvador, 브라질, 41253-190
- 모병
- Hospital Sao Rafael (Rede Dor)
-
São Paulo, 브라질, 05652-900
- 모병
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
-
São Paulo, 브라질, 04014-002
- 모병
- Instituto Brasileiro de Controle Do Cancer
-
São Paulo, 브라질, 01401-004
- 모병
- Instituto Dor de Pesquisa E Ensino Sao Paulo
-
Vitória, 브라질, 29043-260
- 모병
- Hospital Santa Rita de Cassia Afecc
-
-
-
-
-
Caba, 아르헨티나, CP1114
- 모병
- FUNDALEU
-
Caba, 아르헨티나, C1431
- 모병
- CEMIC
-
Caba, 아르헨티나, 1425
- 모병
- Hospital Aleman
-
Ciudad Autonoma Buenos Aires, 아르헨티나, 1413
- 모병
- Hospital Italiano de Buenos Aires
-
Ciudad Autonoma Buenos Aires, 아르헨티나, 1426
- 모병
- Instituto Alexander Fleming (Iaf)
-
San Miguel de Tucumán, 아르헨티나, 4000
- 모병
- Cice 9 de Julio Sanatorio 9 de Julio
-
-
-
-
-
Aberdeen, 영국, AB25 2ZN
- 모병
- Aberdeen Royal Infirmary
-
Birmingham, 영국, B9 5SS
- 모병
- Birmingham Heartlands Hospital
-
Bournemouth, 영국, BH7 7DW
- 모병
- The Royal Bournemouth and Christchurch Hospitals Nhs Foundation
-
London, 영국, SW3 6JJ
- 모병
- Royal Marsden Hospital
-
London, 영국, NW1 2PG
- 모병
- University College Hospital
-
Southampton, 영국, SO16 6YD
- 모병
- Southampton General Hospital
-
-
-
-
-
Bari, 이탈리아, 70124
- 모병
- Irccs Istituto Tumori Giovanni Paolo Ii
-
Florence, 이탈리아, 50134
- 모병
- Aou Careggi, Servizio Sanitario Toscana
-
Milan, 이탈리아, 20132
- 모병
- Ospedale San Raffaele
-
Milan, 이탈리아, 20122
- 모병
- Fondazione Irccs Ca Granda Ospedale Maggiore Policlinico
-
Naples, 이탈리아, 80131
- 모병
- Azienda Ospedaliera Universitaria Federico Ii
-
Novara, 이탈리아, 28100
- 모병
- Aou Maggiore Della Carita
-
Pavia, 이탈리아, 27100
- 모병
- Irccs Policlinico San Matteo, Universita Degli Studi Di Pavi
-
Perugia, 이탈리아, 6129
- 모병
- Ospedale Santa Maria Della Misericordia
-
Roma, 이탈리아, 00168
- 모병
- Fondazione Policlinico Universitario Agostino Gemelli
-
-
-
-
-
Kumamoto, 일본, 860-8556
- 모병
- Kumamoto University Hospital
-
Okayama, 일본, 701-1192
- 모병
- National Hospital Organization Okayama Medical Center
-
Osaka, 일본, 545-8586
- 모병
- Osaka Metropolitan University Hospital
-
-
Aichi-ken
-
Nagoya, Aichi-ken, 일본, 464-8681
- 모병
- Aichi Cancer Center Hospital Clinical Oncology
-
-
Chiba
-
Chiba, Chiba, 일본, 260-8717
- 모병
- Chiba Cancer Center
-
-
Ehime
-
Matsuyama, Ehime, 일본, 791-0280
- 모병
- Nho Shikoku Cancer Center
-
-
Hiroshima
-
Hiroshima, Hiroshima, 일본, 730-8619
- 모병
- Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital
-
-
Hokkaido
-
Sapporo, Hokkaido, 일본, 064-0804
- 모병
- Aiiku Hospital
-
-
Hyōgo
-
AmagasakiCity, Hyōgo, 일본, 660-8550
- 모병
- Hyogo Prefectural Amagasaki General Medical Center
-
-
Kagoshima-ken
-
Kagoshima, Kagoshima-ken, 일본, 890-8520
- 모병
- Kagoshima University Hospital
-
-
Kyoto
-
KyotoShi, Kyoto, 일본, 602-8566
- 모병
- University Hospital, Kyoto Prefectural Univ of Medicine
-
-
Miyagi
-
Sendai, Miyagi, 일본, 980-8574
- 모병
- Tohoku University Hospital
-
-
Niigata
-
Niigata, Niigata, 일본, 951-8520
- 모병
- Niigata University Medical and Dental Hospital
-
-
Okayama-ken
-
Kurashikishi, Okayama-ken, 일본, 710-8602
- 모병
- Kurashiki Central Hospital
-
-
Osaka
-
Hirakata, Osaka, 일본, 573-1191
- 모병
- Kansai Medical University Hospital
-
Sakai, Osaka, 일본, 590-0197
- 모병
- Kindai University Hospital
-
-
Saitama
-
Kawagoeshi, Saitama, 일본, 350-8550
- 모병
- Saitama Medical Center
-
-
Tokyo
-
Bunkyoku, Tokyo, 일본, 113-8677
- 모병
- Tokyo Metropolitan Komagome Hospital
-
Shinagawaku, Tokyo, 일본, 141-0022
- 모병
- Ntt Medical Center Tokyo
-
-
-
-
-
Brno, 체코, 625 00
- 모병
- Fakultni Nemocnice Brno
-
Hradec Králové, 체코, 500 03
- 모병
- Fakultni Nemocnice Hradec Kralove
-
Ostrava, 체코, 708 00
- 모병
- Fakultni Nemocnice Ostrava
-
Prague, 체코, 10000
- 모병
- Vseobecna Fakultni Nemocnice V Praze
-
-
-
-
Ontario
-
Hamilton, Ontario, 캐나다, L8V 5C2
- 모병
- Juravinski Cancer Centre
-
London, Ontario, 캐나다, N6A 5W9
- 모병
- London Health Sciences Centre
-
Ottawa, Ontario, 캐나다, K1H 8L6
- 모병
- The Ottawa Hospital Cancer Centre
-
-
Quebec
-
Greenfield Park, Quebec, 캐나다, J4V 2H1
- 모병
- Centre Integre de Sante Et de Services Sociaux de La Monteregie Centre
-
Montreal, Quebec, 캐나다, QC H3t 1E2
- 모병
- Jewish General Hospital
-
SaintJerome, Quebec, 캐나다, J7Z 5T3
- 모병
- Unite de Recherche Clinique Du Cisss Des Laurentides
-
-
-
-
-
Ankara, 터키 (Türkiye), 6500
- 모병
- Gazi University
-
Ankara, 터키 (Türkiye), 06200
- 모병
- Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
-
Balçova, 터키 (Türkiye), 35330
- 모병
- Dokuz Eylul University
-
Dokuma, 터키 (Türkiye), 07025
- 모병
- Antalya Memorial Hospital
-
Sakarya, 터키 (Türkiye), 54100
- 모병
- Sakarya Training and Research Hospital
-
-
-
-
-
Brzozów, 폴란드, 36-200
- 모병
- Szpital Specjalist W Brzozowie,Podkarpacki Osrodek Onkologiczny
-
Katowice, 폴란드, 40-519
- 모병
- Pratia Onkologia Katowice
-
Krakow, 폴란드, 30-727
- 모병
- Pratia McM Krakow
-
Lodz, 폴란드, 93-510
- 모병
- Wojewodzkie Wielospecjalistyczne Centrum Onkologii I Traumatologii Im M Kopernika W Lodzi
-
Lublin, 폴란드, 20-090
- 모병
- Uniwersytecki Szpital Kliniczny Nr 4 W Lublinie
-
Wroclaw, 폴란드, 50-367
- 모병
- Uniwersytecki Szpital Kliniczny Im Jana Mikulicza Radeckiego We Wroclawiu
-
-
-
-
New South Wales
-
Concord, New South Wales, 호주, NSW 2139
- 모병
- Concord Repatriation General Hospital
-
Gosford, New South Wales, 호주, NSW 2250
- 모병
- Gosford Hospital
-
Port Macquarie, New South Wales, 호주, NSW 2444
- 모병
- Port Macquarie Base Hospital
-
Randwick, New South Wales, 호주, NSW 2031
- 모병
- Prince of Wales Hospital
-
-
Queensland
-
Toowoomba, Queensland, 호주, QLD 4350
- 모병
- Toowoomba Hospital
-
-
South Australia
-
Bedford PK, South Australia, 호주, SA 5042
- 모병
- Flinders Medical Centre
-
-
Victoria
-
Melbourne, Victoria, 호주, VIC 3004
- 모병
- The Alfred Hospital
-
-
Western Australia
-
West Perth, Western Australia, 호주, WA 6005
- 모병
- Perth Blood Institute
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Confirmed diagnosis of CLL or SLL, requiring treatment, based on 2018 international workshop on chronic lymphocytic leukemia (iwCLL) criteria.
- Previously received treatment for CLL/SLL with both a BTKi and a BCL2i.
- Participants with SLL must have measurable disease by computer tomography (CT)/magnetic resonance imaging (MRI).
- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.
- Adequate liver function.
- Adequate blood clotting function.
Exclusion Criteria:
- Known prolymphocytic leukemia (defined per iwCLL 2018 as prolymphocytes comprising >55% of peripheral blood lymphocytes), or currently suspected or history of Richter's transformation within the last 5 years.
- Prior autologous stem cell transplant or chimeric antigen receptor-T cell therapy in the last 6 months.
- Known central nervous system involvement.
- Prior exposure to any BTK protein degraders.
- Active fungal, bacterial and/or viral infection requiring parenteral systemic therapy.
- Clinically significant cardiovascular disease.
- Prior invasive fungal infection, except if patient agrees to receive secondary antifungal prophylaxis during the entire treatment period.
- Known contraindications to azole antifungal agents, including hypersensitivity reactions.
- Receiving systemic immunosuppressive therapy for a nonmalignant condition within 28 days before the first dose of study treatment.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Arm A: Tacabrutideg monotherapy
Participants will receive tacabrutideg once daily until any of the treatment discontinuation criteria are met |
Administered orally
다른 이름들:
|
|
활성 비교기: Arm B: Investigator's Choice
Participants will receive investigator's choice of idelalisib plus rituximab for CLL only or bendamustine plus rituximab, or venetoclax plus rituximab retreatment. |
Administered orally Administered intravenously Administered intravenously Administered orally |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Progression-Free Survival (PFS) by Independent Review Committee (IRC)
기간: Approximately 36 Months
|
PFS is defined as time from the date of randomization to the date of first disease progression or death, whichever occurs first, as determined by IRC using modified 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria for participants with chronic lymphocytic leukemia (CLL) and Lugano classification for participants with small lymphocytic lymphoma (SLL). |
Approximately 36 Months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall Survival (OS)
기간: Approximately 36 Months
|
OS is defined as time from the date of randomization to the date of death due to any cause. |
Approximately 36 Months
|
|
PFS by the Investigator Assessment
기간: Approximately 36 Months
|
PFS is defined as time from the date of randomization to the date of first disease progression or death, whichever occurs first, as determined by the investigator using modified 2018 iwCLL criteria for participants with CLL and Lugano classification for participants with SLL |
Approximately 36 Months
|
|
Rate of Partial Response with Lymphocytosis (PR-L) or Higher Determined by IRC and by Investigator Assessment
기간: Approximately 36 Months
|
Rate of PR-L or higher is defined as the percentage of participants with a best overall response of CR, CRi, nPR, PR, or PR-L as assessed by the IRC or by the Investigator |
Approximately 36 Months
|
|
Duration of Response (DOR) by IRC and Investigator Assessment
기간: Approximately 36 Months
|
DOR is defined as the time from initial response to disease progression or death, whichever occurs first, as assessed by the IRC or by the investigator. |
Approximately 36 Months
|
|
Time to Next Anti-CLL/SLL Treatment (TTNT)
기간: Approximately 36 Months
|
TTNT is defined as the time from the date of randomization to the date of next anti-CLL/SLL treatment. |
Approximately 36 Months
|
|
Change from baseline in EORTC Quality of Life Questionnaire - Chronic Lymphocytic Leukemia Module 17 Items (QLQ-CLL17) Symptom Burden and Physical Condition Scales
기간: Approximately 24 Months
|
The symptom burden and physical condition will be measured by QLQ-CLL17. EORTC QLQ-CLL17 comprises 17 items grouped into 3 multi-item scales: 1) symptom burden, 2) physical condition/fatigue, and 3) worries/fears about health and functioning. Each question is rated using a 4-point response scale ("not at all," "a little," "quite a bit," and "very much") and the recall period for all items is the past 7 days. The scores of each subscale are calculated based on the EORTC's protocol and then transformed to a 0 to 100 scale. Higher scores represent higher levels of symptom burden, physical condition/fatigue, or worries/fears about health and functioning. |
Approximately 24 Months
|
|
Progression-Free Survival (PFS) in Participants with Prior Exposure to Noncovalent Bruton Tyrosine Kinase Inhibitor(s) (ncBTKi) by IRC
기간: Approximately 36 Months
|
PFS is defined as time from the date of randomization to the date of first disease progression or death, whichever occurs first, as determined by IRC using modified 2018 iwCLL criteria for participants with chronic lymphocytic leukemia (CLL) and Lugano classification for participants with small lymphocytic lymphoma (SLL) for participants with prior exposure to ncBTKi. |
Approximately 36 Months
|
|
Overall Response Rate (ORR) by IRC and Investigator Assessment
기간: Approximately 36 Months
|
ORR is defined as the percentage of participants with best overall response of complete response (CR), complete response with incomplete bone marrow recovery (CRi), nodular partial remission (nPR), or partial response (PR) as assessed by the IRC or by the investigator. |
Approximately 36 Months
|
|
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and Laboratory Abnormalities
기간: Approximately 36 Months
|
Safety will be assessed by monitoring and recording of all treatment emergent adverse events (AEs) graded by National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0. |
Approximately 36 Months
|
|
Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status/QoL (GHS) Physical Functioning and Role Functioning Scales
기간: Approximately 24 Months
|
The EORTC QLQ-C30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales(fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1=Not at all (best) to 4=Very Much (worst) and 2 questions answered on a 7-point scale where 1=Very poor (worst) to 7=Excellent (best). Higher scores in GHS and functional scales indicate better quality of life. |
Approximately 24 Months
|
공동 작업자 및 조사자
스폰서
수사관
- 연구 책임자: Study Director, BeOne Medicines
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 병리학적 과정
- 신생물
- 만성 질환
- 질병 속성
- 면역계 질환
- 조직학적 유형에 따른 신생물
- 혈액 질환
- 림프계 질환
- 림프 증식 장애
- 면역증식성 장애
- 백혈병, B세포
- 백혈병, 림프
- 백혈병
- 병리학적 상태, 징후 및 증상
- 헴 및 림프병
- 백혈병, 림프구성, 만성, B세포
- 아미노산, 펩티드 및 단백질
- 단백질
- 유기 화학 물질
- 이종 사이 클릭 화합물
- Benzimidazoles
- 이종 사이 클릭 화합물, 2- 링
- 이종 사이 클릭 화합물, 융합 링
- 탄화수소
- 산, acyclic
- 카르 복실 산
- 항체, 모노클로 날
- 항체
- 면역 글로불린
- 면역 단백질
- 혈액 단백질
- 혈청 글로불린
- 글로불린
- 질소 머스타드 화합물
- 겨자 화합물
- 탄화수소, 할로겐화
- 부티레이트
- 항체, 모노클로 날, 뮤린 유래
- 벤다무스틴 염산염
- 리툭시맙
- Venetoclax
- Idelalisib
기타 연구 ID 번호
- BGB-16673-302
- 2024-518893-15-00 (씨티스)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.
BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.
Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
IPD 공유 기간
See plan description
IPD 공유 액세스 기준
See plan description
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- CSR
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .